Thyroid Surgery Educational Video
OtherAccepting educational video on postoperative TSH suppression therapy for differentiated thyroid cancer created by researchers based on guidelines
NCT Number: NCT07823543
The researchers aim to evaluate the performance of two groups of participants after receiving traditional education-one group supplemented with video-based education and the other without. This study will explore the feasibility of using guideline-based public education videos on postoperative TSH suppression therapy for differentiated thyroid cancer in the context of public education regarding thyroid surgery.
Trial opening soon.
Get Notified18 year–60 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Accepting educational video on postoperative TSH suppression therapy for differentiated thyroid cancer created by researchers based on guidelines
Time frame: Postoperative Month 1, Postoperative Month 3, Postoperative Month 6, and Postoperative Month 12
The criteria for determining the TSH target achievement rate are based on a combination of three factors: the patient's postoperative recurrence risk stratification, the follow-up time point, and the current TSH test result. Within one year postoperatively, the TSH suppression targets are < 0.1 mU/L for the high-risk group, 0.1-0.5 mU/L for the moderate-risk group, and 0.1-0.5 mU/L (low Tg) or 0.5-2 mU/L (undetectable Tg, lobectomy) for the low-risk group. In statistical analysis, the TSH target range attainment rate = (number of patients with TSH levels within the target range at each follow-up time point / total number of patients followed up at that time point) × 100%
Time frame: Immediately after the educational presentation (post-intervention)
Patient satisfaction following different educational approaches was assessed using a 5-point Likert scale (1-5 scale; the higher the score, the higher the satisfaction).
Time frame: Postoperative Month 1, Postoperative Month 3, Postoperative Month 6, and Postoperative Month 12
Knowledge assessment consists of 6 multiple-choice questions, 2 true/false questions, and 2 fill-in-the-blank questions to evaluate patients' understanding and awareness of educational topic.
Time frame: Baseline (before the educational outreach) and immediately after the educational outreach; two assessments total
Anxiety scale, thereby assessing the patient's level of anxiety. A 5-point Likert scale was used, with each item scored on a scale of 1 to 5, ranging from "not at all" to "very severe."
Time frame: Baseline (before the educational outreach) and immediately after the educational outreach
Regret Scale, thereby recording the patient's degree of postoperative regret. 1. This was the right decision.
Time frame: Postoperative Month 1, Postoperative Month 3, and Postoperative Month 6
Whether the patient has forgotten to take medication or mistakenly recorded the follow-up appointment time, etc.
West China Hospital
Other
Patient Education on Postoperative TSH Suppression Therapy for Differentiated Thyroid Cancer Using Science Popularization Videos: A Prospective, Multicenter, Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05428371
Endocrine Gland Neoplasms, Endocrine System Diseases
Cagliari, CA, Italy
View Trial DetailsNCT07428057
Calcium Metabolism Disorders, Endocrine Gland Neoplasms
Minya, Minya Governorate, Egypt
View Trial DetailsNCT05025046
Endocrine Gland Neoplasms, Endocrine System Diseases
Changzhou, Jiangsu, China
View Trial DetailsNCT06738888
Endocrine Gland Neoplasms, Endocrine System Diseases
Shanghai, China
View Trial Details